Multipotent mesenchymal stromal cells in kidney transplant recipients: The next big thing?
Cell Differentiation
/ drug effects
Cell Proliferation
/ drug effects
Humans
Immune Tolerance
/ drug effects
Immunomodulation
/ drug effects
Immunosuppressive Agents
/ administration & dosage
Kidney Transplantation
Lymphocyte Activation
/ drug effects
Mesenchymal Stem Cells
/ cytology
T-Lymphocyte Subsets
/ drug effects
Transplantation Immunology
Immune tolerance
Immunomodulation
Kidney transplantation
Mesenchymal stem cells
Mesenchymal stromal cells
Regulatory T-cells
T-lymphocytes
Journal
Blood reviews
ISSN: 1532-1681
Titre abrégé: Blood Rev
Pays: England
ID NLM: 8708558
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
09
07
2019
revised:
13
04
2020
accepted:
11
05
2020
pubmed:
9
6
2020
medline:
4
9
2021
entrez:
9
6
2020
Statut:
ppublish
Résumé
Bone marrow-derived multipotent mesenchymal stromal cells (BM-MSCs) are non-haematopoietic cells present in the bone marrow stroma. They have the potential to modulate immune responses and exhibit a capacity to promote immune tolerance. Although the efficacy of immunosuppressive drugs has improved significantly, thereby ameliorating renal graft outcome, the use of these drugs still carries an increased risk of malignancies and opportunistic infections, and sometimes fail to prevent chronic allograft rejection or recurrence of the original kidney disease. As such, there is strong interest in ways to induce immune tolerance and thereby tempering or avoiding conventional immunosuppressive drugs. Cellular immunomodulation by MSCs can create a new way to induce transplant tolerance. This review will give a critical overview of the use of BM-MSCs as a cell-based immunosuppressive therapy in kidney transplant recipients. In vitro studies revealed several mechanisms that can clarify the immunomodulatory potential of BM-MSCs. Several clinical studies showed that BM-MSCs can modulate T-cell proliferation and can alter the ratio of T-cell subsets, favoring immune tolerance. However, this immunomodulation was often not associated with better clinical outcome during follow-up when compared to control groups. Some clinical studies found that BM-MSCs allow a reduction in dose of conventional immunosuppressive drugs and prevent acute graft dysfunction. Most clinical studies emphasized that BM-MSC infusion was safe. This review suggests that the use of BM-MSCs as cell-based immunosuppression therapy in kidney transplant recipients has potential, however some caution regarding their clinical use is appropriate. Mechanisms by which BM-MSCs induce transplant tolerance and factors that can alter their functionality need to be analyzed in more detail before clinical use.
Identifiants
pubmed: 32507576
pii: S0268-960X(20)30068-0
doi: 10.1016/j.blre.2020.100718
pii:
doi:
Substances chimiques
Immunosuppressive Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
100718Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.